Auf die besondere Stoffwechselsituation einstellen - Welche Medikamente für den koronarkranken Diabetiker?

Zusammenfassung

Diabetiker müssen mit den gleichen Präventionsmaßnahmen für Herz und Kreislauf behandelt werden wie Nichtdiabetiker, die bereits einen Herzinfarkt erlebt und überlebt haben - dies machen aktuelle Studiendaten deutlich. Bei einer Koronarintervention sollten alle Diabetiker einen Drug-eluting-Stent erhalten und im Rahmen der Intervention mit einem Glykoprotein-IIb/IIIa-Rezeptorenblocker behandelt werden. Doch nicht nur bei der interventionellen koronaren Therapie muss man sich auf die besondere Stoffwechselsituation beim Diabetiker einstellen. So müssen beim Diabetiker bereits leicht erhöhte Blutdruckwerte konsequent behandelt werden. Essenziell ist dabei vor allem die AT₁-Rezeptorblockade, weil diese die diabetische Stoffwechselsituation besonders günstig beeinflussen kann. Aber auch die Therapie mit einem CSE-Hemmer ist bei Diabetikern indiziert - sowohl in der Primär- als auch in der Sekundärtherapie und insbesondere nach einer Koronarintervention.

Data from recent studies show that in diabetics the same measures for the prevention of cardiovascular disease apply as in non-diabetics who have already suffered and survived a myocardial infarction. All diabetics needing a coronary intervention should receive a drug-eluting stent, as well as medication with a glycoprotein IIb/IIIa receptor blocker. However, the need to take account of the particular metabolic situation presenting in diabetics is not confined to treatment with a coronary intervention. For example, diabetics with even mildly elevated blood pressure values need meticulous management. An essential aspect of such therapy is AT₁ receptor blockade, since this can have a particularly favourable impact on the metabolic state in diabetics. But treatment with a CSE inhibitor is also indicated, both in the primary and secondary treatment of diabetics, and in particular following a coronary intervention.

coronary intervention - PTCA - bypass - stents - platelet inhibitor - statins - AT₁ receptor blockade

Literatur

• 1 [No authors listed] . Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status.  J Am Coll Cardiol. 2000;  35 1122-1129
• 2 Colhoun HM, Betteridge DG, Durrington PH. et al. . Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).  Diabetologia. 2005;  48 2482-2485
• 3 Colhoun HM, Betteridge DJ, Durrington PN. et al. . Primary prevention of cardiovascular disease with Atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial.  Lancet. 2004;  364 685-696
• 4 Hansson L, Lindholm LH, Niskanen L. et al. . Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial.  Lancet. 1999;  353 611-616
• 5 Hermiller JB, Raizner A, Cannon L. et al. . Outcomes with the polymer-based Paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV-trial.  J Am Coll Cardiol. 2005;  45 1206-1212
• 6 Islam MA, Blankenship JC, Balog C. et al. . Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).  Am J Cardiol. 2002;  90 916-921
• 7 Moses JW, Leon MB, Popma JJ. et al. . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.  N Engl J Med. 2003;  349 1315-1323
• 8 Pyorala K, Pedersen TR, Kjekshus J. et al. . Simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study.  Diabetes Care. 1997;  20 614-620
• 9 Schupp M, Janke J, Clasen R. et al. . Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.  Circulation. 2004;  109 2054-2057
• 10 Serreus PW, Lemos PA, van Hout BA. Arterial Revascularisation Therapies Study part II Steering Committee and Investigators. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).  Heart. 2004;  90 995-998
• 11 Serruys PW. ARTS I - the rapamycin eluting stent; ARTS II - the rosy prophecy.  Eur Heart J. 2002;  23 757-759

1 National Hispanic/Latino Diabetes

2 Bypass Angioplasty Revascularization Investigation

3 Arterial Revasularisation Therapy Study

4 Sirolimus-eluting Stent

5 Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial

6 Scandinavian Simvastatin Survival Study

7 Collaborative Atorvastatin Diabetes Study

8 UK Prospective Diabetes Study

9 CAPtopril Prevention Project

10 Losartan Intervention For Endpoint reduction in hypertension

11 Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity

12 Valsartan Antihypertensive Long-term Use Evaluation

13 Antihypertensive and Lipid-Lowering treatment do prevent Heart-Attack-Trial

Anschrift des Verfassers